These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7507283)

  • 1. Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses.
    Arnold GF; Resnick DA; Li Y; Zhang A; Smith AD; Geisler SC; Jacobo-Molina A; Lee W; Webster RG; Arnold E
    Virology; 1994 Feb; 198(2):703-8. PubMed ID: 7507283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.
    Smith AD; Resnick DA; Zhang A; Geisler SC; Arnold E; Arnold GF
    J Virol; 1994 Jan; 68(1):575-9. PubMed ID: 8254775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.
    Zhang A; Geisler SC; Smith AD; Resnick DA; Li ML; Wang CY; Looney DJ; Wong-Staal F; Arnold E; Arnold GF
    Biol Chem; 1999 Mar; 380(3):365-74. PubMed ID: 10223339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
    Smith AD; Geisler SC; Chen AA; Resnick DA; Roy BM; Lewi PJ; Arnold E; Arnold GF
    J Virol; 1998 Jan; 72(1):651-9. PubMed ID: 9420270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.
    Resnick DA; Smith AD; Zhang A; Geisler SC; Arnold E; Arnold GF
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S47-52. PubMed ID: 7865333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The construction and characterization of poliovirus antigen chimeras presenting defined regions of the human T lymphocyte marker CD4.
    Rose C; Andrews W; Ferguson M; McKeating J; Almond J; Evans D
    J Gen Virol; 1994 May; 75 ( Pt 5)():969-77. PubMed ID: 8176383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of a poliovirus/rhinovirus antigenic hybrid.
    Altmeyer R; Murdin AD; Harber JJ; Wimmer E
    Virology; 1991 Oct; 184(2):636-44. PubMed ID: 1653493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1.
    Kalyan NK; Lee SG; Wilhelm J; Pisano MR; Hum WT; Hsiao CL; Davis AR; Eichberg JW; Robert-Guroff M; Hung PP
    Vaccine; 1994 Jun; 12(8):753-60. PubMed ID: 7522383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
    Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.
    Dedieu JF; Ronco J; van der Werf S; Hogle JM; Henin Y; Girard M
    J Virol; 1992 May; 66(5):3161-7. PubMed ID: 1373205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of a foreign epitope on the surface of the adenovirus hexon.
    Crompton J; Toogood CI; Wallis N; Hay RT
    J Gen Virol; 1994 Jan; 75 ( Pt 1)():133-9. PubMed ID: 7509367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.
    Vella C; Ferguson M; Dunn G; Meloen R; Langedijk H; Evans D; Minor PD
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2603-7. PubMed ID: 7506299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes.
    Arnold GF; Resnick DA; Smith AD; Geisler SC; Holmes AK; Arnold E
    Intervirology; 1996; 39(1-2):72-8. PubMed ID: 8957672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
    Binley JM; Sanders RW; Clas B; Schuelke N; Master A; Guo Y; Kajumo F; Anselma DJ; Maddon PJ; Olson WC; Moore JP
    J Virol; 2000 Jan; 74(2):627-43. PubMed ID: 10623724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.
    Porta C; Spall VE; Loveland J; Johnson JE; Barker PJ; Lomonossoff GP
    Virology; 1994 Aug; 202(2):949-55. PubMed ID: 8030255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the three-dimensional structure of two human rhinoviruses (HRV2 and HRV14).
    Blaas D; Kuechler E; Vriend G; Arnold E; Luo M; Rossmann MG
    Proteins; 1987; 2(4):263-72. PubMed ID: 2834716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle.
    Hadfield AT; Lee Wm; Zhao R; Oliveira MA; Minor I; Rueckert RR; Rossmann MG
    Structure; 1997 Mar; 5(3):427-41. PubMed ID: 9083115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.
    Marusic C; Rizza P; Lattanzi L; Mancini C; Spada M; Belardelli F; Benvenuto E; Capone I
    J Virol; 2001 Sep; 75(18):8434-9. PubMed ID: 11507188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.
    Sherry B; Mosser AG; Colonno RJ; Rueckert RR
    J Virol; 1986 Jan; 57(1):246-57. PubMed ID: 2416951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.